US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by ImmunoPrecise Antibodies
IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
June 13, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
June 06, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
May 30, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
IPA to Present at Jefferies Healthcare Conference 2023
May 17, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
March 30, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
March 27, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
March 23, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
March 15, 2023
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
December 08, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
November 30, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
BCTX
BCTXW
IPA
TSX:BCT
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
September 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
TSX-V:IPA
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
August 29, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
April 20, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
TSX-V:IPA
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
July 12, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
April 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
May 09, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
March 29, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
June 22, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
June 17, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
June 15, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche
June 02, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board
May 25, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
May 20, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
April 08, 2021
From
ImmunoPrecise Antibodies
Via
Business Wire
Tickers
IPA
